CLL

Patients with inactive early-stage chronic lymphocytic leukemia may benefit from a wait-and-watch approach compared with immediate treatment with Imbruvica, findings from a phase 3 trial showed.

An ongoing trial is examining Calquence in older or frail patients with chronic lymphocytic leukemia — a group that is typically left out of clinical trials.

Days before I went on vacation, I learned that my blood cancer might have progressed to a more aggressive disease.

Before leaving on vacation, I had to make sure I had enough of my cancer medication to last me through the trip.

Findings from a study demonstrated that patients may develop hypertension, or high blood pressure, as a result of treatment with Imbruvica for CLL, although it may be quickly managed without drug-drug interactions.

An ultrasound revealed a solid mass in my breast that would need further follow-up.

A phase 1/1b trial will examine PRGN-3007 in patients with ROR1-positive hematologic and solid cancers.

Here’s a look back at the cancer drugs that gained FDA approval in the winter of 2023.

Personalized medicine means not only more powerful drugs for cancers, but also more precise mechanisms that target the specific consequence of mutations and other alterations that drive cancer cell growth, sparing normal cells.

Bruton tyrosine kinase inhibitors have changed the space for treating patients with CLL or SLL, with more on the way to potentially address drug resistance.

When I share my story and use my cancer diagnosis to help others, cancer becomes a “club” that’s a little more inviting.

Laughter helped me get through many of cancer’s uncomfortable situations, including a recent MRI, where I was laughing despite not being able to move.

The TRANSCNED CLL 004 trial met its primary endpoint of complete responses with the CAR-T cell therapy Breyanzi in patients with relapsed or refractory CLL or SLL.

Two experts explain what patients need to know about the recent approval of Brukinsa for patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

The Food and Drug Administration approved Brukinsa for patients with chronic lymphocytic leukemia or small lymphocytic leukemia.

Life looks a bit different after my cancer diagnosis and the COVID-19 pandemic, making me even more grateful for the people in my life.

When cancer entered our life, fear was a constant. However, we tried to live as joyously as possible between check-ups.

Progression-free survival and overall response rates greatly improved in patients with CLL/SLL treated with Brukinsa compared with Imbruvica.

Patients with chronic lymphocytic leukemia tended to switch to another regimen or intensify their Calquence treatment quicker than those given Imbruvica, study results showed.

Once I got the hang of administering subcutaneous immunoglobulin, my life was so much easier, as I no longer had to undergo monthly IV infusions for my cancer-related compromised immune system.

After being diagnosed with cancer 13 years ago, I began to wonder if my diet had anything to do with it — so I made some changes to eat better.

I made a point to continue baking a weekly challah bread after I was diagnosed with blood cancer, and it proved to be therapeutic.

After being diagnosed with lymphoma, I scheduled consultations with three oncologists, but only one provided me with the hope I needed.

Investigators of an expanded clinical trial have administered an investigational CAR-T cell therapy to the first patient with blood cancer.

Long-term clinical trial data showed that the use of Copiktra was associated with an increased rate of death and severe side effects for patients with chronic lymphocytic leukemia and small cell leukemia.

Treatment with Venclexta plus Gazyva, with or without Imbruvica, led to better outcomes than chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Long-term study results show that outcomes, such as survival and response rates, in patients who have received Calquence-containing treatment regimens continue to outpace outcomes in those who were given Gazyva and chemotherapy.

A panel of experts on the FDA’s Oncologic Drugs Advisory Committee voted that all future approvals of PI3K inhibitors to treat blood cancer be backed by randomized clinical trial data.

The pharmaceutical company developing a combination regimen of ublituximab plus Ukoniq (known as U2) pulled the drug duo’s indications for the treatment of multiple types of blood cancer after clinical trial results fell short of improving overall survival.

The FDA’s partial hold means that no new patients with either leukemia or lymphoma can be enrolled onto the trial.